+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Serum Propeptides of Type I and III Procollagens in Renal Transplant Recipients

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Chronic cyclosporine nephrotoxicity is characterized morphologically by cortical interstitial fibrosis. The most important collagens involved in renal fibrosis are collagen types I and III. In order to estimate the synthesis of type III and type I collagens, we analyzed serum levels of the amino-terminal propeptide of type III procollagen (PIIINP) and the carboxy-terminal propeptide of type I procollagen (PICP) in 11 renal transplant recipients receiving cyclosporine (group CY) and a comparable group of 16 renal transplant recipients treated with azathioprine (group AZ). In addition, 27 healthy subjects and 15 patients with chronic renal disease and reduced renal function (group CRD) were examined. The cyclosporine-treated patients had serum PIIINP and PICP similar to the azathioprine-treated patients. Both groups of renal transplant recipients had significantly increased serum PIIINP compared to healthy controls (2p < 0.01) and serum PIIINP levels similar to group CRD in which serum PIIINP was also elevated compared to healthy controls (2p < 0.01). Mean serum PIIINP levels were: group CY 0.81 U/l (n = 11); group AZ 0.98 U/l (n = 16); controls 0.62 U/l (n = 27); and group CRD 1.06 U/l (n = 15). The renal graft recipients – both cyclosporine- and azathioprine-treated patients – had significantly increased PICP serum levels compared to healthy controls, but the patients with chronic renal disease had serum PICP levels which did not differ from that of healthy controls. Mean serum PICP levels were: group CY 174 μg/l; group AZ 151 μg/l; controls 106 μg/l; and group CRD 119 μg/l. A significant positive correlation was seen between serum creatinine and serum PIIINP in the renal graft recipients (r = 0.51, p < 0.01), but not in the patients with chronic renal disease (r =-0.009, p = 0.49). The data point to an increased synthesis of type I and III collagens in renal transplant recipients. The graft is most likely the source of the increased serum PIIINP and PICP levels. It is suggested that the increased serum levels of propeptides derived from collagen metabolism may reflect continuous immunological destruction of renal tissue causing inflammation and fibrosis.

          Related collections

          Author and article information

          S. Karger AG
          17 December 2008
          : 67
          : 2
          : 203-208
          aDepartment of Clinical Chemistry, Aarhus Amtssygehus, Aarhus University Hospital, and bDepartment of Medicine and Nephrology C, Skejby Hospital, Aarhus University Hospital, Aarhus, Denmark
          187929 Nephron 1994;67:203–208
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article